Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,964 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes in the first year of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome.
Origuchi T, Arima K, Umeda M, Kawashiri SY, Tamai M, Nakamura H, Tsukada T, Miyashita T, Iwanaga N, Izumi Y, Furuyama M, Tanaka F, Kawabe Y, Aramaki T, Ueki Y, Eguchi K, Fukuda T, Kawakami A. Origuchi T, et al. Among authors: fukuda t. Mod Rheumatol. 2017 Jan;27(1):150-154. doi: 10.1080/14397595.2016.1192744. Epub 2016 Jun 20. Mod Rheumatol. 2017. PMID: 27320419
Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, Mine M, Ida H, Origuchi T, Aoyagi K, Eguchi K. Iwamoto N, et al. Among authors: fukuda t. Mod Rheumatol. 2009;19(5):488-92. doi: 10.1007/s10165-009-0187-8. Epub 2009 Jul 4. Mod Rheumatol. 2009. PMID: 19578932
Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor.
Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, Arima K, Nakamura H, Yamasaki S, Ida H, Kawakami A, Ueki Y, Matsuoka N, Nakashima M, Mizokami A, Kawabe Y, Mine M, Fukuda T, Eguchi K. Origuchi T, et al. Among authors: fukuda t. Mod Rheumatol. 2011 Jun;21(3):244-50. doi: 10.1007/s10165-010-0384-5. Epub 2010 Dec 29. Mod Rheumatol. 2011. PMID: 21188454
High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome.
Origuchi T, Arima K, Kawashiri SY, Tamai M, Yamasaki S, Nakamura H, Tsukada T, Aramaki T, Furuyama M, Miyashita T, Kawabe Y, Iwanaga N, Terada K, Ueki Y, Fukuda T, Eguchi K, Kawakami A. Origuchi T, et al. Among authors: fukuda t. Mod Rheumatol. 2012 Aug;22(4):584-8. doi: 10.1007/s10165-011-0556-y. Epub 2011 Nov 17. Mod Rheumatol. 2012. PMID: 22089392
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M; Iguratimod-Clinical Study Group. Ishiguro N, et al. Mod Rheumatol. 2013 May;23(3):430-9. doi: 10.1007/s10165-012-0724-8. Epub 2012 Jul 26. Mod Rheumatol. 2013. PMID: 22833377 Clinical Trial.
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K; Iguratimod-Clinical Study Group. Hara M, et al. Mod Rheumatol. 2014 May;24(3):410-8. doi: 10.3109/14397595.2013.843756. Epub 2013 Nov 7. Mod Rheumatol. 2014. PMID: 24252050 Clinical Trial.
4,964 results